Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- Conditions
- Pulmonary EmbolismDeep Vein Thrombosis
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3221
- Registration Number
- NCT00452530
- Locations
- 🇬🇧
Local Institution, Epsom, Surrey, United Kingdom
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
- Conditions
- Deep Vein ThrombosisPulmonary Embolism
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5407
- Registration Number
- NCT00423319
- Locations
- 🇺🇸
Shrock Orthopedic Research, Ft. Lauderdale, Florida, United States
🇺🇸Orthoarkansas, P.A., Little Rock, Arkansas, United States
🇺🇸Pab Clinical Research, Brandon, Florida, United States
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
- Conditions
- Atrial FibrillationAtrial Flutter
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20976
- Registration Number
- NCT00412984
- Locations
- 🇺🇸
David Charles Mishkel, Md, Pa, Boca Raton, Florida, United States
🇺🇸Heart Care Center, P.C., East Syracuse, New York, United States
🇺🇸Elkhart Clinic, Llc, Elkhart, Indiana, United States
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
- Conditions
- Pulmonary EmbolismCancerThrombosis
- Interventions
- Drug: PlaceboDrug: Apixaban
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT00320255
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mount Sinai School Of Medicine, New York, New York, United States
Safety Study of Apixaban in Recent Acute Coronary Syndrome
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1741
- Registration Number
- NCT00313300
- Locations
- 🇺🇸
Midwest Cardiology Research Foundation, Columbus, Ohio, United States
🇺🇸Georgia Heart Specialists, Covington, Georgia, United States
🇺🇸Heartcare Midwest, Peoria, Illinois, United States
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
- Conditions
- Deep-Vein Thrombosis
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 520
- Registration Number
- NCT00252005
- Locations
- 🇸🇪
Local Institution, Vastervik, Sweden
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
- Conditions
- Venous ThrombosisPulmonary Embolism
- Interventions
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1238
- Registration Number
- NCT00097357
- Locations
- 🇵🇷
Local Institution, Ponce, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.